With new clinical trials of APR-246 commencing in multiple tumour streams 2 , our discovery of SLC7A11 expression as a robust companion biomarker, in addition to mut-p53 status, for APR-246, may facilitate selection and enrichment of patients with mut-p53 tumours who are most likely to respond to APR-246 therapy
To summarize existing candidates for clinical radioprotectors, we conducted a literature review using a Pubmed/MEDLINE search with key phrases including: antioxidants in medical imaging, antioxidants in radiotherapy, antioxidant radiation, radioprotective agents, radioprotective radiotherapy, radioprotective medical imaging, and radioprotection. To be included, the articles were required to be peer-reviewed primary research articles published in the past 10 years that investigated one or more substances as potential radioprotective agents
The most important safety point is honesty about the evidence: Epithalon is a research peptide, not a regulated medication, and the long-term human data remain incomplete
An IV push typically takes just minutes, while an IM injection is administered into the muscle tissue